Cambrex Corporation, the leading manufacturer of small molecule innovator and generic active pharmaceutical ingredients (APIs), has announced that it has completed the installation of new, large-scale manufacturing capacity at its cGMP facility in Karlskoga, Sweden and has also undertaken a multi-year construction project to increase the site’s waste water processing capabilities.
The expansion of the site’s manufacturing capabilities included the installation of various multipurpose reactors, ranging from 4–12 m3 in size, in addition to a 9 m³ hydrogenation reactor.
The construction of a new waste water treatment plant to support the expansion and improve existing biological processes, is being phased during a 3-year period.
The $3.5 million investment will process more than 4000 m3 of water each day and handle variations in the composition of effluent.
The majority of the construction project will be completed in 2017, with additional upgrades in 2018 and 2019. When completed, the facility will reduce the emission of nitrogen, total organic compounds and suspended material, improving the site’s environmental footprint.
“Our Karlskoga site is a crucial part of the company’s global manufacturing network, and these investments, which not only increase its capacity, but also add to the supporting infrastructure, will enable the site to work efficiently both now and into the future,” commented Bjarne Sandberg, Managing Director, Cambrex Karlskoga.
He added: “At Cambrex, we are committed to investing in small molecule development and manufacturing capabilities, and ensuring our facilities are both flexible and efficient to respond to the evolving needs of our customers.”
The expansion at Cambrex’s Swedish site is part of an ongoing strategic campaign to increase manufacturing capacity across its global network, and follows the announcement of the construction of a $24 million, ,500 sq. ft highly potent API manufacturing facility at the Charles City (Iowa, USA) site, which is due to open in 2019.